All Community pharmacist articles
-
InformationGINA ASTHMA STRATEGY 2020
Asthma affects an estimated 300 million individuals worldwide, and still imposes an unacceptable burden on healthcare systems, society through loss of productivity in the workplace, and, especially for paediatric asthma, disruption to the family. Asthma affects all age groups and contributes to many deaths worldwide. The Global Initiative for ...
-
Information
Key COVID-19 guidance for community pharmacy
The Guidelines for Pharmacy team has produced the following directory of COVID-19 information and guidance for community pharmacy. Included on this page is a collection of key guidance and advice from PSNC, FIP, and NHS, as well as a list of information for specific groups from a range of ...
-
Information
Key COVID-19 guidance for primary care
The Guidelines team has produced the following directory of COVID-19 information and guidance for primary care. Included on this page is a collection of key guidance and advice from PHE and the NHS, as well as a list of information for specific groups from a range of professional bodies. ...
-
Independent professional body guideline
GINA strategy 2020: assessing patients with asthma
This Guidelines summary outlines recommendations for assessing patients with asthma. Please refer to the full report for the complete set of recommendations.
-
Independent professional body guideline
GINA strategy 2020: asthma–COPD overlap
This Guidelines summary outlines recommendations for the diagnosis and initial treatment of adults with features of asthma, chronic obstructive pulmonary disease (COPD), or both.
-
Independent professional body guideline
GINA strategy 2020: diagnosis of asthma
This Guidelines summary outlines recommendations for making the diagnosis of asthma in adults and children over five years of age. Please refer to the full report for the complete set of recommendations.
-
PHE/DH/DWP guideline
PHE influenza immunisation guideline
This Guidelines summary covers key points for administering influenza immunisation, and who should receive it.
-
NHS guideline
NHS guidance on NSAIDs in COVID-19
This summary sets out the clinical policy for the acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19.
-
PHE/DH/DWP guideline
PHE guideline on management of exposure to COVID-19
This summary provides guidance on the management of staff and patients in health and social care settings according to exposures, symptoms, and test results.
-
Independent professional body guideline
FSRH UKMEC contraception guideline
A summary of the FSRH UKMEC guidance on the safety of contraceptive methods, which is set out in clear and concise tables.
-
Independent professional body guideline
ROS guideline: vitamin D and bone health in children
A clear summary on the management of vitamin D deficiency in children and young people.
-
PHE/DH/DWP guideline
COVID-19 personal protective equipment (PPE)
This revised guidance concerns use of personal protective equipment (PPE) by health and social care workers, in the context of the current COVID-19 pandemic.
-
Independent professional body guideline
PCDS management of acne guideline
A concise summary of the Primary Care Dermatology Society's guideline on the treatment of acne vulgaris.
-
Independent professional body guideline
PCDS atopic eczema guideline
An overview of the management of atopic eczema. Covers taking a clinical history, step-by-step treatment, and includes an eczema management plan.
-
PHE/DH/DWP guideline
PHE pneumococcal vaccination guideline (Green Book chapter 25)
A succinct summary of Public Health England’s Green Book chapter 25 pneumococcal vaccination programme
-
Independent professional body guideline
Recognition and management of sepsis in general practice
This Guidelines summary combines recommendations from The UK Sepsis Trust to give guidance on the recognition and management of sepsis in adults, children, and young people over 12 years of age
-
NHS guideline
NHS England COVID-19 community pharmacy guideline
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title and therefore only covers the information relevant to this setting. This guidance is correct at the time of publishing. The Guidelines team review the information daily and update as ...
-
NICE guideline
COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders
The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources
-
NICE guideline
COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response
The purpose of this Guidelines summary is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic.
-
Independent professional body guideline
Recommended actions after incorrect use of combined hormonal contraception
This Guidelines summary guides management for when a woman has made a mistake using combined oral contraceptive pills, combined vaginal ring, and combined transdermal patch.
